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Abstract Inadequate serum 25-hydroxyvitamin D (25[OH]
D) concentrations are associated with muscle weakness,
decreased physical performance, and increased propensity in
falls and fractures. This paper discusses several aspects with
regard to vitamin D status and supplementation when
treating patients with osteoporosis in relation to risks and
prevention of falls and fractures. Based on evidence from
literature, adequate supplementation with at least 700 IU of
vitamin D, preferably cholecalciferol, is required for improv-
ing physical function and prevention of falls and fractures.
Additional calcium supplementation may be considered
when dietary calcium intake is below 700 mg/day. For
optimal bone mineral density response in patients treated
with antiresorptive or anabolic therapy, adequate vitamin D
and calcium supplementation is also necessary. Monitoring
of 25(OH)D levels during follow-up and adjustment of
vitamin D supplementation should be considered to reach
and maintain adequate serum 25(OH)D levels of at least
50 nmol/L, preferably greater than 75 nmol/L in all patients.




Osteoporosis is a chronic, progressive disease characterized
by reduced bone mass and microarchitectural deterioration of
bone, involving an extensive fragility and a subsequent
increase in fracture risk [1]. Fracture risk increases with age
and is often associated with an increased bone remodeling
resulting in bone resorption, loss of bone strength, and
decrease of bone mineral density (BMD) [2]. More than 90%
of fractures occur after a fall and fall rates increase with age
postural instability and/or quadriceps weakness [3].
Inadequate serum 25-hydroxyvitamin D (25[OH]D)
concentrations are associated with decreased intestinal
calcium absorption causing compensatory increase in
parathyroid hormone (PTH) levels and thus secondary
hyperparathyroidism leading to a lower degree of mineral-
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DOI 10.1007/s11914-010-0041-0ization and accelerated bone loss [4, 5]. Declining vitamin
D levels are also associated with muscle weakness,
decreased balance and physical performance, and increased
propensity in falls and fractures [6–8]. Vitamin D insuffi-
ciency has now been linked to a broad spectrum of human
diseases from cancer to cardiovascular to autoimmune
conditions, but these topics are out of the scope of this
paper [9]. In this paper we discuss several aspects with
regard to vitamin D status and supplementation when
treating osteoporosis in relation to risks and prevention of
falls and fractures based on a number of recently published
meta-analyses.
Vitamin D Status
The stages of vitamin D deficiency are generally defined
based on circulating 25(OH)D levels, in which a serum
level less than 12.5 nmol/L is defined as severe deficiency,
a level between 12.5 and 25 nmol/L as deficiency, and a
level of 25 to 50 nmol/L as vitamin D insufficiency [5]. The
1,25-dihydroxyvitamin D assay should not be used for
detecting vitamin D deficiency because levels will be
normal or even elevated as a result of secondary hyper-
parathyroidism [10]. Several end points can be used for
defining optimal vitamin D status in terms of 25(OH)D
levels: prevention of PTH elevation, optimal muscle
function, prevention of bone loss, falls or fractures.
Relationship Between 25(OH)D and PTH Levels
and Vitamin D Supplementation
PTH is secreted in response to reduced calcium levels
causing an increase in bone resorption and subsequently
normalization of calcium levels. In case of vitamin D
deficiency, secondary hyperparathyroidism results in in-
creased bone turnover and bone loss and may subsequently
increase fracture risk [5]. The relationship between 25(OH)
D and PTH levels has been described in several cross-
sectional studies, indicating a significant negative correla-
tion between PTH and 25(OH)D values with only a
minimal increase of PTH when serum 25(OH)D is above
50 to 75 nmol/L [11, 12, 13￿, 14]. Recently, Carnevale et al.
[14] demonstrated that PTH levels were mainly determined
by 25(OH)D levels up to 40 nmol/L and to serum ionized
calcium at levels greater than 40 nmol/L in healthy
volunteers. In a recent study it has been shown that for
the same 25-OHD level, PTH levels were comparable
across genders but were 1.5- to twofold higher in the
elderly compared with adolescents [15] and that elevated
PTH is a strong independent predictor for poor outcomes in
older patients [16, 17].
Vitamin D3 supplementation (cholecalciferol) with a dose
of 600 IU/day during 4 months decreased median serum
PTH levels by 23% in elderly nursing home residents who
had mean baseline 25(OH)D levels of 25.0 nmol/L. Calcium
supplementation had no effect on serum PTH [18]. In
osteoporosis patients, 25(OH)D increased and PTH decreased
more in those taking 3000 IU of vitamin D per day compared
with 800 IU/day. An increase of 25(OH)D≥75 nmol/L
resulted in normalized PTH [19]. In contrast, in healthy
men and women between 20 and 80 years with a baseline 25
(OH)D level of 67 nmol/L, acute ingestion of a 600-mg
calcium carbonate lowered PTH and bone turnover markers,
whereas additional intake of 4000 IU/day of vitamin D3 did
not lower PTH or markers of bone turnover [20]. This is in
line with previous findings that PTH levels do not decrease
after vitamin D supplementation [21] or only marginally
decreased after vitamin D and calcium supplementation in
subjects with baseline 25(OH)D levels ≥50 nmol/L [22].
From these data it seems apparent that vitamin D supple-
mentation decreases PTH levels up to a 25(OH)D level of
50 nmol/L and that calcium supplementation might addi-
tionally lower PTH when 25(OH)D is ≥50 nmol/L.
Relationship Between 25(OH)D Levels, Neuromuscular
Function, and Vitamin D Supplementation
The nuclear receptor for vitamin D (VDR) is expressed in
many human cell types, including muscle cells [10, 23].
Older age is associated with decreased VDR expression,
independent of serum 25(OH)D levels [24]. The effect of
vitamin D on muscle tissue is thought to occur through
specific VDRs. Cross-sectional studies show that elderly
people with deficient 25(OH)D serum levels have muscle
weakness, particularly in proximal muscles, associated to a
decrease in motion ability and capabilities, which increases
the number of falls [25, 26]. A serum 25(OH)D level below
50 nmol/L is associated with increased body sway and a
level below 30 nmol/L with decreased muscle strength [27].
In a prospective, population-based study, Visser et al. [28]
showed that low 25(OH)D levels and high PTH levels
increased the risk of sarcopenia in subjects 65 years of age
or older. In both active and inactive ambulatory persons
aged ≥60 years of age, 25(OH)D concentrations ≥40 nmol/
L were associated with better musculoskeletal function in
the lower extremities than concentrations less than 40 nmol/
L[ 29] and in serum 25(OH)D concentrations below
50 nmol/L were associated with poorer physical perfor-
mance and a greater decline in physical performance in men
and women ≥65 years of age [7]. In randomized controlled
trials (RCTs), vitamin D supplementation increased muscle
strength and balance with 800 IU of vitamin D on top of
calcium substitution [30, 31]. However, in a recent study by
Curr Osteoporos Rep (2011) 9:36–42 37Lips et al. [32], weekly treatment with 8400 IU of vitamin
D did not reduce mediolateral sway significantly compared
with treatment with placebo in subjects ≥70 years of age,
with serum 25(OH)D levels between 15 and 50 nmol/L,
although in post hoc analysis, treatment with 8400 IU of
vitamin D per week reduced sway in the subgroup of
patients who had elevated sway at baseline. Based on these
results it seems likely that vitamin D substitution improves
physical performance and that those with severe vitamin D
deficiency experience the greatest benefit.
Relationship Between 25(OH)D Levels, Risk of Falling,
and Vitamin D Supplementation
A beneficial effect of vitamin D supplementation on fall
prevention among ambulatory or institutionalized older indi-
viduals with stable health bymore than 20% was suggested by
the meta-analysis of Bischoff-Ferrari et al. [33]. This meta-
analysis was based on five RCTs involving 1237 participants
treated with cholecalciferol or active vitamin D analogues
compared with patients receiving calcium or placebo. The
benefit was most clearly established for women and with
active vitamin D analogues [33]. Active forms of vitamin D
do not need hydroxylation in the kidney, so their effect on
falls should be influenced less by age-related decline in
kidney function than the effect of supplemental vitamin D. In
2008 one meta-analysis showed that active vitamin D
supplementation seemed to prevent falls to a greater extent
than their native compound [34] and in another small meta-
analysis with combined data of two trials a significant risk
reduction of falls was also demonstrated [35].
In a more recent meta-analysis the efficacy of vitamin D
supplementation was assessed for the prevention of falls
among older persons by dose and serum concentration of
25(OH)D achieved [36]. In this analysis 10 RCTS trials
were included: three with ergocalciferol, five with chole-
calciferol, and two with active forms of vitamin D doses
(one with alfacalcidol and one with calcitriol). Dosages of
supplemental vitamin D of 700 to 1000 IU/day could
reduce falls by 19% or by up to 26% with ergocalciferol,
independent of additional calcium supplementation. Vita-
min D doses below 700 IU a day did not prevent falls. A 25
(OH)D concentration of at least 60 nmol/L was required for
fall prevention. From this analysis it seems likely that
greater benefits may be achieved with vitamin D3 instead of
vitamin D2. Active forms of vitamin D do not appear to be
more effective than 700 to 1000 IU of vitamin D for fall
prevention in this analysis [36].
In the Cochrane review of interventions for preventing
falls in older people living in the community, the efficacy
for fall prevention of supplementation with vitamin D or an
analogue, either alone or with calcium co-supplementation,
was analyzed [37]. The overall analysis of vitamin D versus
control did not show a statistically significant difference in
rate of falls or risk of falling in 10 studies with 21,110
participants. In a post hoc subgroup analysis the rate of falls
was significantly reduced in trials recruiting participants
with lower (<50 nmol/L) baseline 25(OH)D levels (relative
risk [RR], 0.57; 95% CI, 0.37–0.89 in 260 participants, two
trials) but not in participants not so selected (RR, 1.02; 95%
CI, 0.88–1.19 in 3669 participants, three trials). For
calcitriol but not alfacalcidol a significant reduction in rate
of falls and risk of falling was reported; however, there was
also a significant increase in the risk of hypercalcemia [37].
The Cochrane review of interventions for preventing
falls in older people in nursing care facilities and hospitals
reported a significant reduction of the rate of falls (RR,
0.72; 95% CI, 0.55–0.95, 4512 participants in four trials;
one with cholecalciferol and three with ergocalciferol),
although the number of fallers was not significantly
different (RR, 0.98; 95% CI, 0.89–1.09, 5095 participants
in five trials; two with cholecalciferol and three with
ergocalciferol) with vitamin D supplementation compared
with placebo or calcium in nursing care facilities [38].
Average serum 25(OH)D levels were between 22 and
47 nmol/L in the included studies. Caution may be required
with interpretation of these pooled data because of
statistical and clinical heterogeneity.
In the most recent review including 10 RCTs, vitamin D
treatment effectively reduced the risk of falls with 14% in
community dwelling and institutionalized older adults with
a mean age from 71 to 92 years [39]. Three types of
vitamin D (six studies with cholecalciferol, three with
ergocalciferol, and one with alfacalcidol) were used. In
seven studies patients used additional calcium therapy and
in three studies no additional medication was used.
Treatment duration ranged between 1 and 36 months, and
native vitamin D dosage ranged between 200 and 1000 IU.
The effect of vitamin D on fall reduction was significant in
several subgroups of individuals: mean age younger than
80 years, additional calcium therapy, no history of fracture
or fall, dose of 800 IU or greater, cholecalciferol therapy,
duration of treatment longer than 6 months, although no
evidence was found of a relationship between higher doses
of vitamin D or longer duration of vitamin D therapy and
treatment effect [39]. It has to be noted that all studies
included in the meta-analysis had populations with 25(OH)
D levels less than 75 nmol/L.
Relationship Between 25(OH)D Levels, Risk
of Fractures, and Vitamin D Supplementation
During the past years several meta-analysis have been
published on the effect of vitamin D with and without
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42, 43￿￿, 44￿￿, 45, 46￿￿]. The analysis of Bischoff-Ferrari et
al. [40], including five RCTs for hip fracture (n=9294) and
seven RCTs for nonvertebral fracture risk (n=9820),
concluded that vitamin D dose of 700 to 800 IU/day
reduced the relative risk of hip fracture by 26% (three RCTs
with 5572 persons; pooled RR, 0.74; 95% CI, 0.61–0.88)
and of any nonvertebral fracture by 23% (five RCTs with
6098 persons; pooled RR, 0.77; 95% CI, 0.68–0.87) versus
calcium or placebo in individuals ≥60 years of age. No
significant benefit was observed for RCTs with 400 IU/day
of vitamin D (two RCTs with 3722 persons) [40]. The
meta-analysis by Boonen et al. [41], designed to extend the
findings of Bischoff-Ferrari et al. [40], suggested that only
vitamin D with additional calcium demonstrated a signif-
icant reduction of hip and nonvertebral fractures versus
placebo or no treatment. A total of 53,260 patients from
nine RCTs were included in this analysis and all RCTs used
cholecalciferol with a dose of 700 to 800 IU/day in six trials
and 400 IU/day in the other three trials. Calcium (500–
1200 mg/d) was given with vitamin D in six RCTs. In an
adjusted indirect comparison further support was found for
combined supplementation of vitamin D and calcium, with
a 25% reduction in hip fracture risk compared with vitamin
D alone and it was suggested that oral vitamin D appears to
reduce the risk of hip fractures only when calcium supple-
mentationisadded[41]. It has to be noted that two trials with
very low nutritional baseline calcium intake had an important
impact on the results of this meta-analysis [47, 48].
The meta-analysis of Tang et al. [42] showed that
calcium supplementation, alone or in combination with
vitamin D, was effective in the preventive treatment of
osteoporotic fracture. The fracture risk reduction was greater
inindividualswhowereelderly,livingininstitutions,andhad
a low baseline calcium intake. Treatment was similarly
effective whether persons used calcium or calcium in
combination with vitamin D supplementation. However, the
treatment was less effective if compliance was lower than
80%. For calcium-only supplementation, a minimum dose of
1200 mg was needed for best therapeutic effect. For calcium
in combination with vitamin D supplementation, a minimum
dose of 800 IU of vitamin D was recommended. There was
no significant difference in fracture reduction between low
versusnormal25(OH)Dserumconcentrationatbaseline[42].
In the more recent analysis by Bischoff-Ferrari [43￿￿],
which included 12 RCTs for nonvertebral fractures (two
with ergocalciferol, 10 with cholecalciferol; n=42,279) and
eight RCTs for hip fractures (n=40,886) in individuals
65 years or older, the antifracture efficacy of supplemental
vitamin D increased significantly with higher received dose
or higher achieved 25(OH)D levels (>75 nmol/L) for any
nonvertebral fractures and for hip fractures. No fracture
reduction was observed for a dose of 400 IU/day or less,
whereas a higher dose of 482 to 770 IU/day of supplemen-
tal vitamin D reduced nonvertebral fractures by 20% and
hip fractures by 18%. Subgroup analyses for the prevention
of nonvertebral fractures with the higher received dose
suggested possibly better fracture reduction with cholecal-
ciferol compared with ergocalciferol, whereas additional
calcium did not further improve antifracture efficacy [43￿￿].
The analysis by Bergman et al. [45] supports the use of
cholecalciferol 800 IU daily to reduce the incidence of
osteoporotic nonvertebral, hip, and nonvertebral–non-hip
fractures in women over 50 years of age. In this study,
cholecalciferol with calcium appears to achieve benefits
above those attained with calcium supplementation alone
for nonvertebral and nonvertebral–non-hip fractures [45].
The Cochrane meta-analysis suggested that vitamin D
alone appeared unlikely to be effective in preventing hip
fracture (nine trials, 24,749 participants; RR, 1.15; 95% CI,
0.99–1.33), vertebral fracture (five trials, 9138 participants;
RR, 0.90; 95% CI, 0.42–1.92), or any new fracture (10
trials, 25,016 participants; RR, 1.01; 95% CI, 0.93–1.09).
Vitamin D with calcium reduced hip fractures (eight trials,
46,658 participants; RR, 0.84; 95% CI, 0.73–0.96) [44￿￿].
In the most recent meta-analysis by the DIPART
(Vitamin D Individual Patient Analysis of Randomized
Trials) group, seven major randomized trials of vitamin D
with calcium or vitamin D alone, with a total of 68,517
participants (mean age 69.9 years; range 47–107 years;
14.7% men) were included [46￿￿]. In this analysis based on
individual patient data analysis it was also indicated that
vitamin D with calcium showed a reduced overall risk of
fracture (hazard ratio [HR], 0.92; 95% CI, 0.86–0.99; P=
0.025) and hip fracture (all studies: 0.84, 0.70–1.01; P=
0.07; studies using 400 IU of vitamin D per day given with
calcium: 0.74, 0.60–0.91; P=0.005). Vitamin D given alone
in doses of 400 to 800 IU per day was not effective in
preventing fractures [46￿￿].
Supplementation with high-dose vitamin D supplemen-
tation annually could be harmful. Among 2256 older
community-dwelling women, annual oral administration of
500,000 IU of cholecalciferol resulted in an increased risk
of falls and fractures compared with placebo [49￿]. An
annual intramuscular injection of 300,000 IU of ergocalci-
ferol was not effective in preventing nonvertebral fractures
among 9440 elderly men and women residents in the
general population. The HR for hip fracture was signifi-
cantly increased (HR, 1.49; 95% CI, 1.02–2.18) [50].
Optimal Vitamin D Dose for Reduction of Falls
and Fractures
It seems likely that vitamin D substitution improves
physical performance and that elderly and those with severe
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on evidence from RCTs and the meta-analyses, vitamin D
supplementation reduces both falls and fractures. The
beneficial effect of vitamin D is dose dependent and mainly
demonstrated for cholecalciferol with a dose of at least
700 IU/day. Active vitamin D is not preferred because of
the increased risk of hypercalcemia.
Annually high-dose vitamin D supplementation could
possibly increase fall and fracture risk. It was suggested that
a 25(OH)D concentration of at least 60 nmol/L was
required for fall prevention and optimal fracture prevention
appeared to occur in trials with achieved mean 25(OH)D
levels of approximately 75 to 100 nmol/L. Additionally,
adequate 25(OH)D levels were required for an optimal
BMD response in patients who are being treated with
bisphosphonates for osteoporosis [51], and coadministra-
tion of cholecalciferol and calcium vitamin D with
antiresorptive medication improved the subsequent BMD
response unaffected by vitamin D status at initiation [52,
53]. However, the practical clinical question is whether all
treated patients will receive a 25(OH)D level greater than
60 nmol/L with a vitamin D dose of 700 or 800 IU/day and
if not, what vitamin D intake is needed to achieve serum
concentrations greater than 60 nmol/L. It has been reported
that the rate of increase of 25(OH)D levels was between 0.6
and 1.2 nmol/L per 40 IU daily of vitamin D3 and that the
response may well be an inverse function of the starting 25
(OH)D concentration [54]. Seasonal fluctuations on 25(OH)
D levels may further contribute to insufficient vitamin D
status during winter months, especially in the elderly [55].
Based on these aspects it seems warranted to measure a
baseline 25(OH)D level in all patients who are going to be
treated with antiosteoporosis medication such as patients
with a fracture or low bone mass, and to monitor 25(OH)D
levels during follow-up and to adjust vitamin D supple-
mentation when desired 25(OH)D levels are not achieved.
In patients with severe vitamin D deficiency supplementa-
tion may be started with cholecalciferol 20,000 to
50,000 IU/week orally for 3 months until 25(OH)D levels
are at least 50 nmol/L, followed by a daily dose of at least
700 IU. Higher dosages may be necessary when desired 25
(OH)D levels are not maintained [19, 56].
In addition to vitamin D status, calcium balance must be
optimized. For persons older than 50 years, a total calcium
intake of 1000 to 1200 mg per day was advised [57].
Calcium supplementation may be needed when dietary
calcium intake is insufficient, although a calcium intake
greater than 700 mg/day may be only beneficial for better
BMD when 25(OH)D levels are less than 50 nmol/L [58￿].
The meta-analysis by Bischoff-Ferrari et al. [59] showed no
reduction in hip fracture risk with calcium supplementation.
In addition, recent publications suggest an increased risk of
myocardial infarction with calcium supplementation with-
out coadministration of vitamin D [60]. However, the risk of
myocardial infarction was not increased in people with
dietary calcium intake below a median dietary calcium intake
of 805 mg/day [60]. Thus, calcium supplementation may be
considered when dietary calcium intake is below 700 mg/day,
with a calcium supplementation dose that leads to a
maximum total daily calcium intake of 1000 to 1200 mg.
Conclusions
Poor vitamin D status and low calcium intake are important
determinates for osteoporosis and fracture risk. Based on
evidence from literature, adequate supplementation with at
least 700 IU of vitamin D, preferably cholecalciferol, is
required for improving physical function and prevention of
falls and fractures. Additional calcium supplementation
may be considered when dietary calcium intake is below
700 mg/day, with a supplementation dose that leads to a
maximum total daily calcium intake of 1000 to 1200 mg.
For optimal BMD response in patients treated with
antiresorptive or anabolic therapy, adequate vitamin D and
calcium supplementation is also necessary. It should be
considered to monitor 25(OH)D levels during follow-up of
patients with osteoporosis to warrant adequate vitamin D
status during treatment and if necessary adjust the vitamin
D supplementation dose to reach or maintain 25(OH)D
levels of at least 50 nmol/L, preferably greater than
75 nmol/L in all patients.
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